Previous Close | 179.33 |
Open | 178.78 |
Bid | 171.59 x 1200 |
Ask | 177.51 x 1000 |
Day's Range | 174.55 - 179.04 |
52 Week Range | 105.43 - 192.79 |
Volume | |
Avg. Volume | 1,354,301 |
Market Cap | 32.499B |
Beta (5Y Monthly) | 0.82 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.84 |
Earnings Date | Apr 27, 2022 - May 02, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 159.88 |
SVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc (NYSE: MRK) from a potential acquisition of Seagen Inc (NASDAQ: SGEN). The analysts refrain from commenting on the probability of the deal happening. The analysis suggests that the short-term impact on EPS from the potential acquisition will likely be meaningfully dilutive. Related: Merck Shows Takeover Interest In Seagen: WSJ. According to SVB, the deal decreases forecasted GAAP EPS by -12%, -7%, and -2% in
Seattle Genetics (SGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Does the June share price for Seagen Inc. ( NASDAQ:SGEN ) reflect what it's really worth? Today, we will estimate the...